From 1 October, Poland’s new reimbursement list will include 24 new therapies, including 13 oncology, 11 non-oncology and eight therapies for rare diseases. The list includes new treatments for biliary tract, colorectal, gastric and oesophageal cancers, as well as targeted therapy for von Hippel-Lindau syndrome.
“Two weeks ago, a decree from the Minister of Health came into effect, giving us new tools for negotiating with pharmaceutical companies. During that time, we held talks with eleven entities. The result of these negotiations is PLN 400 million. This money will go to patients to finance further therapies.”
Katarzyna Kacperczyk, Deputy Minister of Health
Kacperczyk also highlighted changes to drug reimbursement for seniors, which introduced a competitive mechanism and the possibility of reimbursing cheaper alternatives.
“Please be honest. There is no need to scare seniors or cause anxiety. Our mechanism is based on new negotiation tools, not on removing drugs from reimbursement lists. I deny the press reports and assure you that 1,500 drugs are not and will not disappear from senior lists,” she said.
The new list includes oncology indications for bile duct, colorectal, gastric and oesophageal cancers, as well as haematological cancers. Targeted therapies for von Hippel-Lindau syndrome will also be reimbursed for the first time.
New non-oncology indications include treatments for cystic fibrosis, amyloid cardiomyopathy, primary biliary cholangitis, Duchenne muscular dystrophy and pulmonary hypertension in children.
The list also includes 10 established therapies in endocrinology that will be available through pharmacies.
Kacperczyk noted that this is the fourth and final reimbursement list of 2026.
“This year, we have already reimbursed 90 new therapies, including 46 oncology and 44 non-oncology therapies, with 30 intended for patients with rare diseases. As many as one-third of all new therapies are for rare diseases. These are the most expensive therapies, and without reimbursement, patients would not be able to afford them or start treatment,” Kacperczyk said.
This year, the National Health Fund (NFZ) received PLN 2.4 billion through risk-sharing agreements, allowing it to fund new therapies and continue reimbursement for existing treatments. Revenue from risk-sharing instruments established in 2026 could exceed PLN 3 billion.
